{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T15:48:01Z","timestamp":1783784881209,"version":"3.55.0"},"reference-count":49,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,6,12]],"date-time":"2023-06-12T00:00:00Z","timestamp":1686528000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Introduction:<\/jats:bold> existing research on children consists primarily of phase I\/II clinical trials for VEGFR-TKI. System reports of safety on the use of VEGFR-TKI in pediatrics are lacking.<\/jats:p><jats:p><jats:bold>Aim:<\/jats:bold> to investigate the safety profiles of VEGFR-TKI in pediatrics via the FDA Adverse Event Reporting System (FAERS).<\/jats:p><jats:p><jats:bold>Method:<\/jats:bold> data regarding VEGFR-TKIs were extracted from the FAERS between 2004Q1 to 2022Q3 and categorized by the Medical Dictionary for Regulatory Activities (MedDRA). Population characteristics were analyzed, and reporting odds ratio (ROR) was performed to identify risk signals associated with VEGFR-TKI.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> 53,921 cases containing 561 children were identified in the database from 18 May 2005, to 30 September 2022. Among those in the system organ class, skin, subcutaneous tissue disorders, and blood and lymphatic system disorders in pediatrics contributed to over 140 cases. Palmar-plantar eythrodysesthesia syndrome (PPES) in VEGFR-TKI presented the most significant 340.9 (95% 229.2\u2013507.0). And pneumothorax also gave a high reporting odds ratio of 48.9 (95% 34.7\u201368.9). For a specific drug, musculoskeletal pain gave a ROR of 78.5 (95% 24.4\u2013252.6) in cabozantinib and oesophagitis in lenvatinib with a ROR of 95.2 (95% 29.5\u2013306.9). Additionally, hypothyroidism presented a high signal, especially sunitinib, with a ROR of 107.8 (95% 37.6\u2013308.7).<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> the present study explored the safety profile of VEGFR-TKI in pediatrics using the FAERS database. Multiple skin and subcutaneous tissue disorders, as well as blood and lymphatic system disorders, were common VEGFR-TKI-related AEs in system organ class. No serious hepatobiliary AEs were detected. For the specific AEs, PPES and pneumothorax were VEGFR-TKI-related AEs that presented significantly higher signals than those in the general population.<\/jats:p>","DOI":"10.3389\/fphar.2023.1160117","type":"journal-article","created":{"date-parts":[[2023,6,12]],"date-time":"2023-06-12T04:26:38Z","timestamp":1686543998000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Safety profile of vascular endothelial growth factor receptor tyrosine-kinase inhibitors in pediatrics: a pharmacovigilance disproportionality analysis"],"prefix":"10.3389","volume":"14","author":[{"given":"Yifei","family":"Xue","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuo","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangyao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,6,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e0254866","DOI":"10.1371\/journal.pone.0254866","article-title":"Different patterns of pneumothorax in patients with soft tissue tumors treated with pazopanib: A case series analysis","volume":"16","author":"Aiba","year":"2021","journal-title":"PLoS One"},{"key":"B2","doi-asserted-by":"publisher","first-page":"e28679","DOI":"10.1002\/pbc.28679","article-title":"Composite sarcoma of bone with focal rhabdomyosarcoma and lymph node metastasis in an adolescent","volume":"67","author":"Andi\u00f3n Catal\u00e1n","year":"2020","journal-title":"Pediatr. Blood Cancer"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1016\/j.cell.2019.01.021","article-title":"VEGF in signaling and disease: Beyond discovery and development","volume":"176","author":"Apte","year":"2019","journal-title":"Cell."},{"key":"B4","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1634\/theoncologist.2012-0024","article-title":"The risk for anemia with targeted therapies for solid tumors","volume":"17","author":"Barni","year":"2012","journal-title":"Oncologist"},{"key":"B5","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.semcancer.2020.12.008","article-title":"Effects of tyrosine kinase inhibitors on thyroid function and thyroid hormone metabolism","volume":"79","author":"Basolo","year":"2022","journal-title":"Semin. Cancer Biol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"864790","DOI":"10.3389\/fonc.2022.864790","article-title":"Bevacizumab, with sorafenib and cyclophosphamide provides clinical benefit for recurrent or refractory osseous sarcomas in children and young adults","volume":"12","author":"Bodea","year":"2022","journal-title":"Front. Oncol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"4421","DOI":"10.1111\/bcp.14868","article-title":"Pharmacovigilance-based drug repurposing: The search for inverse signals via OpenVigil identifies putative drugs against viral respiratory infections","volume":"87","author":"Bohm","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"e0157753","DOI":"10.1371\/journal.pone.0157753","article-title":"OpenVigil FDA - inspection of U.S. American adverse drug events pharmacovigilance data and novel clinical applications","volume":"11","author":"Bohm","year":"2016","journal-title":"PLoS One"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1016\/S1470-2045(21)00332-6","article-title":"Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"22","author":"Brose","year":"2021","journal-title":"Lancet Oncol."},{"key":"B10","first-page":"351","article-title":"The assessment of primitive or metastatic malignant pulmonary tumors in children","volume":"108","author":"Burnei","year":"2013","journal-title":"Chir. (Bucur)"},{"key":"B11","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/s40257-016-0197-1","article-title":"Multikinase inhibitor-induced hand-foot skin reaction: A review of clinical presentation, pathogenesis, and management","volume":"17","author":"Chanprapaph","year":"2016","journal-title":"Am. J. Clin. Dermatol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"103186","DOI":"10.1016\/j.critrevonc.2020.103186","article-title":"Bleeding with vascular endothelial growth factor tyrosine kinase inhibitor: A network meta-analysis","volume":"157","author":"Das","year":"2021","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"e071752","DOI":"10.1136\/bmj-2022-071752","article-title":"Characterization and corroboration of safety signals identified from the US food and drug administration adverse event reporting system, 2008-19: Cross sectional study","volume":"379","author":"Dhodapkar","year":"2022","journal-title":"BMJ"},{"key":"B14","doi-asserted-by":"publisher","first-page":"4173","DOI":"10.1158\/1078-0432.CCR-22-0873","article-title":"FDA approval summary: Cabozantinib for differentiated thyroid cancer","volume":"28","author":"Duke","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"B15","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/sj.jidsymp.5650016","article-title":"Molecular mechanisms of VEGF-A action during tissue repair","volume":"11","author":"Eming","year":"2006","journal-title":"J. Investig. Dermatol Symp. Proc."},{"key":"B16","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1210\/er.2003-0027","article-title":"Vascular endothelial growth factor: Basic science and clinical progress","volume":"25","author":"Ferrara","year":"2004","journal-title":"Endocr. Rev."},{"key":"B17","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1038\/nrd.2015.17","article-title":"Ten years of anti-vascular endothelial growth factor therapy","volume":"15","author":"Ferrara","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"key":"B18","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1097\/00000658-197203000-00014","article-title":"Anti-angiogenesis: New concept for therapy of solid tumors","volume":"175","author":"Folkman","year":"1972","journal-title":"Ann. Surg."},{"key":"B19","doi-asserted-by":"publisher","first-page":"100250","DOI":"10.1016\/j.esmoop.2021.100250","article-title":"Phase I\/II study of single-agent lenvatinib in children and adolescents with refractory or relapsed solid malignancies and young adults with osteosarcoma (ITCC-050)","volume":"6","author":"Gaspar","year":"","journal-title":"ESMO Open"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1016\/S1470-2045(21)00387-9","article-title":"Lenvatinib with etoposide plus ifosfamide in patients with refractory or relapsed osteosarcoma (ITCC-050): A multicentre, open-label, multicohort, phase 1\/2 study","volume":"22","author":"Gaspar","year":"","journal-title":"Lancet Oncol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.ejca.2021.05.023","article-title":"Phase 1 dose-escalation and pharmacokinetic study of regorafenib in paediatric patients with recurrent or refractory solid malignancies","volume":"153","author":"Geoerger","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"B22","doi-asserted-by":"publisher","first-page":"163","DOI":"10.4274\/tjh.galenos.2020.2020.0532","article-title":"An interesting case: Sunitinib-induced microangiopathic hemolytic anemia and nephrotic syndrome","volume":"38","author":"Haks\u00f6yler","year":"2021","journal-title":"Turk J. Haematol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1159\/000088282","article-title":"Anaemia of cancer: Impact on patient fatigue and long-term outcome","volume":"69","author":"Harper","year":"2005","journal-title":"Oncology"},{"key":"B24","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1007\/s00432-021-03521-w","article-title":"Comparative evaluation of cardiovascular risks among nine FDA-approved VEGFR-TKIs in patients with solid tumors: A bayesian network analysis of randomized controlled trials","volume":"147","author":"Hou","year":"2021","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1016\/j.jpedsurg.2015.01.005","article-title":"Pneumothorax as a complication of combination antiangiogenic therapy in children and young adults with refractory\/recurrent solid tumors","volume":"50","author":"Interiano","year":"2015","journal-title":"J. Pediatr. Surg."},{"key":"B26","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/S1470-2045(19)30825-3","article-title":"Cabozantinib in patients with advanced ewing sarcoma or osteosarcoma (CABONE): A multicentre, single-arm, phase 2 trial","volume":"21","author":"Italiano","year":"2020","journal-title":"Lancet Oncol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1158\/1078-0432.CCR-07-5134","article-title":"Regulation of hematopoietic stem cells by the steel factor\/KIT signaling pathway","volume":"14","author":"Kent","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1093\/annonc\/mdn389","article-title":"Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib","volume":"19","author":"Lacouture","year":"2008","journal-title":"Ann. Oncol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1002\/ijc.30800","article-title":"Suicidal death of erythrocytes in cancer and its chemotherapy: A potential target in the treatment of tumor-associated anemia","volume":"141","author":"Lang","year":"2017","journal-title":"Int. J. Cancer"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1111\/jcpt.13472","article-title":"Thyroid dysfunction related to vascular endothelial growth factor receptor tyrosine kinase inhibitors: A real-world study based on FAERS","volume":"46","author":"Liao","year":"2021","journal-title":"J. Clin. Pharm. Ther."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1007\/s00520-014-2520-9","article-title":"Tyrosine kinase inhibitors directed against the vascular endothelial growth factor receptor (VEGFR) have distinct cutaneous toxicity profiles: A meta-analysis and review of the literature","volume":"23","author":"Massey","year":"2015","journal-title":"Support Care Cancer"},{"key":"B32","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.immuni.2013.07.005","article-title":"Deciphering and reversing tumor immune suppression","volume":"39","author":"Motz","year":"2013","journal-title":"Immunity"},{"key":"B33","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s12253-017-0228-0","article-title":"Primary ewing sarcoma\/primitive neuroectodermal tumor of the kidney: A clinicopathologic study of 23 cases","volume":"24","author":"Murugan","year":"2018","journal-title":"Pathol. Oncol. Res."},{"key":"B34","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1186\/s12885-018-4858-8","article-title":"Secondary spontaneous pneumothorax in patients with sarcoma treated with Pazopanib, a case control study","volume":"18","author":"Sabath","year":"2018","journal-title":"BMC Cancer"},{"key":"B35","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA adverse event reporting system","volume":"10","author":"Sakaeda","year":"2013","journal-title":"Int. J. Med. Sci."},{"key":"B36","doi-asserted-by":"publisher","first-page":"e28671","DOI":"10.1002\/jmv.28671","article-title":"Association of antiviral drugs and their possible mechanisms with DRESS syndrome using data mining algorithms","volume":"95","author":"Sharma","year":"2023","journal-title":"J. Med. Virol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"5315","DOI":"10.3390\/cancers14215315","article-title":"Safety of anti-angiogenic drugs in pediatric patients with solid tumors: A systematic review and meta-analysis","volume":"14","author":"Spini","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B38","doi-asserted-by":"publisher","first-page":"e143","DOI":"10.1097\/MJT.0b013e3181eefe8b","article-title":"Sunitinib-induced microangiopathic hemolytic anemia with fatal outcome","volume":"19","author":"Talebi","year":"2012","journal-title":"Am. J. Ther."},{"key":"B39","doi-asserted-by":"publisher","first-page":"103457","DOI":"10.1016\/j.critrevonc.2021.103457","article-title":"An overview of current results with the vincristine-irinotecan-temozolomide combination with or without bevacizumab in pediatric, adolescence and adult solid tumors","volume":"166","author":"Tsakatikas","year":"2021","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"e49","DOI":"10.1016\/j.clcc.2017.09.004","article-title":"Clinical features of regorafenib-induced liver injury in Japanese patients from postmarketing experience","volume":"17","author":"Uetake","year":"2018","journal-title":"Clin. Colorectal Cancer"},{"key":"B41","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s00280-019-03814-5","article-title":"Sunitinib in pediatric patients with advanced gastrointestinal stromal tumor: Results from a phase I\/II trial","volume":"84","author":"Verschuur","year":"2019","journal-title":"Cancer Chemother. Pharmacol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1634\/theoncologist.2009-0143","article-title":"Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib","volume":"15","author":"Vincenzi","year":"2010","journal-title":"Oncol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1196\/annals.1392.020","article-title":"Effect of FLT3 inhibition on normal hematopoietic progenitor cells","volume":"1106","author":"Weisel","year":"2007","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1016\/S1470-2045(20)30325-9","article-title":"Pathological response in children and adults with large unresected intermediate-grade or high-grade soft tissue sarcoma receiving preoperative chemoradiotherapy with or without pazopanib (ARST1321): A multicentre, randomised, open-label, phase 2 trial","volume":"21","author":"Weiss","year":"2020","journal-title":"Lancet Oncol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1002\/cam4.713","article-title":"Phase II evaluation of sunitinib in the treatment of recurrent or refractory high-grade glioma or ependymoma in children: A children's oncology group study ACNS1021","volume":"5","author":"Wetmore","year":"2016","journal-title":"Cancer Med."},{"key":"B46","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/leu.2012.191","article-title":"Mutations of FLT3\/ITD confer resistance to multiple tyrosine kinase inhibitors","volume":"27","author":"Williams","year":"2013","journal-title":"Leukemia"},{"key":"B47","doi-asserted-by":"publisher","first-page":"e1256","DOI":"10.1002\/onco.13726","article-title":"Anlotinib, vincristine, and irinotecan for advanced ewing sarcoma after failure of standard multimodal therapy: A two-cohort, phase ib\/II trial","volume":"26","author":"Xu","year":"2021","journal-title":"Oncologist"},{"key":"B48","doi-asserted-by":"publisher","first-page":"e102110","DOI":"10.1371\/journal.pone.0102110","article-title":"Association of toxicity of sorafenib and sunitinib for human keratinocytes with inhibition of signal transduction and activator of transcription 3 (STAT3)","volume":"9","author":"Yamamoto","year":"2014","journal-title":"PLoS One"},{"key":"B49","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1158\/0008-5472.CAN-15-0694","article-title":"Multikinase inhibitors induce cutaneous toxicity through OAT6-mediated uptake and MAP3K7-driven cell death","volume":"76","author":"Zimmerman","year":"2016","journal-title":"Cancer Res."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1160117\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,12]],"date-time":"2023-06-12T04:26:43Z","timestamp":1686544003000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1160117\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,12]]},"references-count":49,"alternative-id":["10.3389\/fphar.2023.1160117"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2023.1160117","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,12]]},"article-number":"1160117"}}